Wegovy Pill vs Wegovy Injection: How Close Are the Results?

Close, as far as anyone can tell, though the two have never been tested against each other ^[1]. In separate placebo-controlled trials, the 25 mg Wegovy tablet produced a mean weight change of −13.6% at week 64 and the 2.4 mg weekly injection produced −14.9% at week 68 ^[2][3]. A Novo Nordisk-sponsored indirect comparison of those trials estimated a difference of 1.01 percentage points in the injection’s favor, with a 95% confidence interval from −1.61 to 3.63 ^[1]. That interval is wide enough to include no gap at all or a modest one. People with type 2 diabetes, and people who want more than the 2.4 mg dose can deliver, face a different comparison.

The two trials, side by side

OASIS 4 and STEP 1 enrolled similar people: adults without diabetes, with a BMI of 30 or higher, or 27 or higher with a weight-related condition, alongside lifestyle support ^[2][3]. Mean baseline weight was 105.9 kg and 105.3 kg, and mean BMI 37.6 and 37.9 ^[1]. Size and geography were the main differences: 307 people were randomized in OASIS 4 and 1,961 in STEP 1 ^[2][3], and STEP 1 enrolled across 16 countries against four for OASIS 4, with 13.3% Asian participants against 0.7% ^[1]. The weight-loss percentages below come from the FDA label, which reports both trials with the same intention-to-treat framing, and the mean changes match the journal reports except for the OASIS 4 placebo arm, which the journal gives as −2.2% with a difference of −11.4 points ^[4][2].

What the indirect comparison found, and what it can bear

Plotkin and colleagues used a naive Bucher comparison, which subtracts one drug’s effect against placebo from the other’s ^[1]. Under the analysis counting everyone regardless of whether they kept taking the drug, the injection’s advantage was 1.01 points (95% CI −1.61 to 3.63). Under the analysis estimating the effect as if everyone stayed on treatment, it was 0.55 points (95% CI −2.25 to 3.35) ^[1]. For reaching a 5% loss under that second analysis, the estimated odds ratio was 0.68 (95% CI 0.34 to 1.38), numerically favoring the injection without showing a clear difference ^[1].

The authors say these results support “therapeutic equivalence” because the gap sits well below the FDA’s 5% threshold for clinical relevance ^[1]. We read that more cautiously, for three reasons:

• Five percent is a yardstick for a drug against placebo. Using it to judge two forms of one drug sets a generous bar. The upper end of the interval, 3.63 points, would amount to about 3.8 kg at these trials’ average starting weight (our arithmetic), which some patients would notice ^[1].
• No randomization links the two. The trials ran years apart, with STEP 1 from June 2018 to April 2020 and OASIS 4 from November 2022 to May 2024, and placebos were given by different routes. The authors say the effect of that placebo difference is unknown ^[1].
• The sponsor has an interest. Novo Nordisk funded the work, three authors were employed by the company at the time, and it contracted the evidence firm that ran the analysis ^[1].

An independent check points in the same general direction. A 262-trial network meta-analysis in The BMJ estimated one-year weight loss against lifestyle modification alone at −10.9% for oral semaglutide (95% CI −12.7 to −9.1) and −9.8% for subcutaneous semaglutide (95% CI −10.6 to −9.1) ^[6]. The overlap fits with no large gap. The abstract does not separate the 25 mg tablet from other oral doses, so this does not isolate the product you would be prescribed ^[6].

Why a 25 mg pill can match a 2.4 mg shot

Almost all of the tablet’s dose never reaches the bloodstream. The label estimates absolute bioavailability at about 1% to 2% for the tablet and 89% for the injection, and the tablet relies on an absorption enhancer called SNAC ^[4]. The two end up in the same place on average: steady-state concentration was about 77 nmol/L on the 25 mg tablet and about 75 nmol/L on the 2.4 mg injection ^[4]. In a modeling analysis by a mostly Novo Nordisk author group, 82.2% of OASIS 4 tablet users had exposure in the same range as STEP 1 injection users ^[5]. That also means a meaningful minority did not, and the label notes higher variability in semaglutide blood concentrations with tablets in all patient populations ^[4][5].

Absorption depends on the routine. The label says to take the tablet in the morning on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines ^[4]. Guidance from trial investigators stresses explaining why these conditions matter before starting treatment ^[9]. Those trial results come from research settings. We found no randomized data on how well people keep up the morning routine in everyday use compared with a weekly injection.

Where the comparison breaks down

Type 2 diabetes

Both OASIS 4 and STEP 1 enrolled people without diabetes, and the label says the tablets “have not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight” ^[2][3][4]. A 2026 modeling paper filled the gap with simulation ^[5]. Its simulated placebo-adjusted weight reduction was 7.8% to 9.4% with diabetes, against 14.7% to 16.3% without, and those are model outputs and not trial results ^[5]. The label states that average concentrations from the tablet were lower than from the 2.4 mg injection in people with type 2 diabetes, and adds this caution ^[4]:

some patients with type 2 diabetes taking WEGOVY tablets may experience subtherapeutic semaglutide blood concentrations.

— Wegovy label, section 8.6

The higher injectable dose

The injection now goes further than 2.4 mg. The label allows an increase to a maximum of 7.2 mg weekly in people who tolerate 2.4 mg for at least 4 weeks and need more weight reduction ^[4]. In STEP UP, 7.2 mg produced a mean change of −18.7%, against −15.6% on 2.4 mg and −3.9% on placebo at 72 weeks, with more gastrointestinal events (70.8% vs 61.2% vs 42.8%) and more dysesthesia, an abnormal skin sensation (22.9% vs 6.0% vs 0.5%) ^[10]. No equivalent higher tablet step appears in the label ^[4].

Heart, liver and age

Both forms carry the indication for reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, but the cardiovascular outcomes trial described in the label was run with the injection ^[4]. The BMJ analysis similarly linked subcutaneous semaglutide to lower all-cause mortality (risk ratio 0.81, 95% CI 0.72 to 0.93), with those estimates largely informed by outcome trials in high-risk people ^[6]. Only the injection is labeled for patients aged 12 and older and for MASH with moderate to advanced fibrosis, the latter under accelerated approval ^[4].

Side effects and tolerability

Reported rates look alike, and no one has formally compared them. Gastrointestinal events affected 74.0% on the tablet and 74.2% on the injection, against 42.2% and 47.9% on their respective placebos; discontinuation because of adverse events was 6.9% and 7.0%, against 5.9% and 3.1% ^[1]. Serious adverse events ran 3.9% on the tablet and 9.8% on the injection, but placebo went the other way (8.8% in OASIS 4 and 6.4% in STEP 1), a hint of how much noise sits in a trial the size of OASIS 4 ^[1]. The label also reports dysesthesia in 5% of tablet users and no placebo users ^[4].

The BMJ network analysis grouped oral semaglutide among the drugs with the highest discontinuation because of adverse events, with risk ratios across that group of 1.9 to 4.2, and among those with the most increased gastrointestinal events, at 3.1 to 4.2. Subcutaneous semaglutide was not named in either group ^[6]. That analysis is not limited to the 25 mg tablet, so it raises a question and does not answer it. Tolerability is also a reason people look beyond semaglutide altogether, and our comparison of Foundayo, Wegovy and Zepbound covers that choice.

Practical differences that can decide it

Moving between the two is built into the label ^[4]. A person on the 2.4 mg injection can start the 25 mg tablet one week after stopping the shot, and a person on the 25 mg tablet can start the 2.4 mg injection the day after the last tablet. For people who do not tolerate the 25 mg tablet, the label says to consider the 1.7 mg injection ^[4]. With a prescriber, it is worth covering whether you have type 2 diabetes, whether a morning fast fits your other medicines, and whether you might need more than 2.4 mg can offer.